Effect of gastric acid‐reducing agents on the pharmacokinetics and efficacy of lemborexant

Lemborexant is a dual orexin receptor antagonist approved for treating insomnia. As the solubility of lemborexant is pH‐sensitive, the impact of the gastric acid‐reducing agent (ARA), famotidine, on lemborexant pharmacokinetics was evaluated in a Phase 1 study. Additionally, post hoc analysis of dat...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Pharmacol Res Perspect
Päätekijät: Landry, Ishani, Aluri, Jagadeesh, Hall, Nancy, Kumar, Dinesh, Dayal, Satish, Moline, Margaret, Reyderman, Larisa
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2020
Aiheet:
Short Report
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7604696/
https://ncbi.nlm.nih.gov/pubmed/33135390
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.678
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia